Hormone Therapy May Boost Weight Loss on Wegovy, But Not as Much on Zepbound

New research shows that using hormone therapy with a GLP-1 during menopause may lead to greater weight loss. Tatsiana Volkava · Moment/Getty A study presented at the 2026 Annual Meeting of The Menopause Society found that women using menopause hormone therapy (MHT) alongside semaglutide (Ozempic, Wegovy) experienced greater weight loss than those taking semaglutide alone. Tirzepatide (Mounjaro, Zepbound) combined with MHT showed only modest early differences in weight loss, with no statistically significant difference at later time points. Certain hormone therapy medications are FDA-approved to treat menopause symptoms such as hot flashes and vaginal dryness, but not for weight loss. Experts recommend individualizing treatment decisions based on symptoms, medical history, and health goals rather than adding MHT solely to enhance weight loss with GLP-1 medications. Females using menopause hormone therapy (MHT) alongside GLP-1 medications such as Ozempic or Wegovy may experience greater weight loss, according to a study presented at the 2026 Annual Meeting of the Menopause Society. Weight gain is a common concern among middle-aged women. While much of this is associated with aging, …

≈